Shawn Scranton

Shawn Scranton is the Chief Scientific Officer for Sentynl Therapeutics, Inc. Knowledgeable and exacting, Dr. Scranton brings more than 20 years of experience in clinical development to the team at Sentynl. Prior to joining the expert team at Sentynl, Dr. Scranton was Vice President of Scientific Operations and Victory Pharmaceuticals for many years. At Victory, his responsibilities included oversight of Clinical, Regulatory, Manufacturing and Medical Affairs functions while bringing two new products to market, as well as managing three pipeline development programs.

“We are pleased to have attracted a person of Dr. Scranton’s caliber, and his strategic medical knowledge signals our focus on bringing products to market and increased growth in sales,” commented Co-Founder, President, and CEO of Sentynl Therapeutics, Inc., Mr. Heck. “As we bring more pharmaceutical products through the pipeline, Dr. Scranton’s contributions will be extremely valuable.” Dr. Scranton observed, “Victory Pharma’s proven management team and recent commercialization successes combined with high potential products currently under development were the key reasons I decided to join the Company.” This enthusiasm for Dr. Scranton’s professionalism continued and followed both Dr. Scranton and Mr. Heck to Sentynl Therapeutics, Inc.

Before Victory, Shawn Scranton’s career saw him at Kalypsys, Inc., with a role as Senior Director of Translational Medicine, wherein he contributed to non-clinical, as well as regulatory and clinical strategies. These efforts led to the successful opening of NCE INDs, and the execution and conducting of clinical programs in neuropathic pain and metabolic disease.

Earlier stops in Dr. Scranton’s career include Director of Clinical Development, and program director of the SDK-101 program for Salmedix, Inc., which was later acquired by Cephalon, as well as Senior Clinical Research Scientist at Dura Pharmaceuticals. He has held academic positions at Baylor college, where he performed as a Principal Investigator on many industry and government-supported clinical trials, at the University of Houston, and also at the University of the Pacific, where he earned his PharmD and additionally completed a fellowship in cardiovascular pharmacology. His B.A. degree in Animal Physiology was earned from University of California, San Diego.

Sentynl Therapeutics seeks to provide professionals in healthcare with solutions for treatment that enables them in meeting the needs of individ